SCHEMBL24252984

SCHEMBL24252984

COc1ccc(CNc2cnnc3cc(-c4cc(Cl)ccc4C(=O)NC(C)C)ccc23)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.43
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
CYP1A2 P05177 5/20 0.38
CYP3A4 P08684 5/20 0.38
CYP2C19 P33261 5/20 0.38
ALDH1A1 P00352 5/20 0.38
HSD17B10 Q99714 4/20 0.38
TSHR P16473 3/20 0.38
LMNA P02545 2/20 0.38
CYP2C9 P11712 2/20 0.38
CLK4 Q9HAZ1 2/20 0.38
GCGR P47871 2/20 0.38
CYP2D6 P10635 2/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 1/20 0.37
USP2 O75604 2/20 0.37
PDE9A O76083 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25237585 0.97 KDM4C (0.41) KDM4CCNR1CNR2TAS1R3TAS1R1
SCHEMBL24252924 0.90 KDM4C (0.52) KDM4CCNR1CNR2TAS1R3TAS1R1
SCHEMBL30452330 0.90 KDM4C (0.52) KDM4CCNR1CNR2TAS1R3TAS1R1
SCHEMBL24252463 0.90 KDM4C (0.45) KDM4CCNR1CNR2TAS1R3TAS1R1
SCHEMBL30451581 0.90 KDM4C (0.45) KDM4CCNR1CNR2TAS1R3TAS1R1
SCHEMBL30467679 0.88 SMN1; SMN2 (0.42) KDM4CCNR1CNR2CYP1A2CYP3A4
SCHEMBL24252436 0.88 SMN1; SMN2 (0.42) KDM4CCNR1CNR2CYP1A2CYP3A4
SCHEMBL30467637 0.87 KDM4C (0.41) KDM4CCNR1CNR2ALDH1A1TSHR
SCHEMBL24252871 0.87 KDM4C (0.41) KDM4CCNR1CNR2ALDH1A1TSHR
SCHEMBL24252808 0.86 CYP1A2 (0.46) KDM4CCNR1CNR2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885CNR1 2075/4885CNR2 1499/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 KDM4C 4542/4885CNR1 2075/4885CNR2 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.